CAR T-Cell Therapy Quality of Life Research
- the quest to understand the long-term effects of innovative cancer treatments is an ongoing journey.
- In 2020, the HHS Juravinski Hospital and Cancer Center (JHCC) marked a meaningful milestone, becoming the frist hospital in Ontario to offer CAR T-cell therapy to lymphoma...
- Balitsky's research is dedicated to identifying potential long-term complications and developing strategies to enhance the quality of life for survivors.
CAR T-Cell Therapy: A New Frontier in Lymphoma Treatment
Table of Contents
the quest to understand the long-term effects of innovative cancer treatments is an ongoing journey. Dr. Amaris Balitsky, a malignant hematologist at Hamilton Health Sciences (HHS), is at the forefront of this effort, specifically studying the lasting impacts of CAR T-cell therapy. This specialized treatment became available to Ontario patients with specific types of lymphoma five years ago.
In 2020, the HHS Juravinski Hospital and Cancer Center (JHCC) marked a meaningful milestone, becoming the frist hospital in Ontario to offer CAR T-cell therapy to lymphoma patients. Furthermore, it was the first in Canada to provide this treatment on an outpatient basis. CAR T-cell therapy has demonstrated the ability to induce remission in lymphoma,even in cases previously deemed incurable. However, due to the novelty of this treatment, the long-term quality of life for survivors remains an area of active investigation.
Dr. Balitsky’s research is dedicated to identifying potential long-term complications and developing strategies to enhance the quality of life for survivors.
“We’re learning from today’s patients, to hopefully help them have the best outcomes as well as building an improved quality of life for tomorrow’s patients.”
According to Dr. Balitsky, a researcher with the Escarpment Cancer Research Institute, located at JHCC, patients desire two primary outcomes from their treatment: “to live longer and live better.” She emphasizes the importance of not only extending patients’ lives but also supporting their pursuit of a good quality of life.
How CAR T-Cell Therapy Works
Conventional lymphoma treatment typically involves a combination of radiation and chemotherapy. Immunotherapy, which harnesses the patient’s immune system to combat cancer, represents a relatively new treatment avenue for various cancers, including lymphomas. This approach offers renewed hope for many patients, including those previously considered incurable.
CAR T-cell therapy is a form of immunotherapy that modifies a patient’s T-cells in a laboratory setting, enabling them to target and destroy cancer cells.This personalized approach is revolutionizing cancer care.
Managing Side Effects of CAR T-Cell Therapy
Like many therapies, CAR T-cell therapy can have side effects. One notable affect is the creation of a cytokine storm, where the body releases chemicals called cytokines, potentially leading to symptoms such as brain inflammation.
Dr.Balitsky notes that while brain swelling is generally reversible, it remains a significant concern for patients. Her research explores whether short-term inflammation can lead to longer-term cognitive issues.
“CART-cell therapy is still so new that we don’t know what, if any, subtle, long-term complications may happen due to inflammation of the brain,” she says. She emphasizes the need for a better understanding of long-term side effects through research,notably regarding cognitive function and potential interventions.
To address thes questions, Dr. Balitsky is conducting a study, funded by the HHS Foundation, involving 40 JHCC patients. The study examines long-term cognition in lymphoma patients undergoing CAR T-cell therapy, with initial data expected in January 2026.
The research includes cognitive tests before treatment and one year after. Additionally, patient-reported fatigue, depression, anxiety, and overall quality of life are being measured. Patients also provide self-reports on any perceived changes in cognition, allowing for a comparison between test results and subjective experiences.
Compiling a Registry of Patients Receiving CAR T-Cell Therapy
Dr.Balitsky is also investigating the geographical aspects of CAR T-cell therapy. As the JHCC is the sole cancer center in south central Ontario offering this therapy, it serves patients from a wide region, including those referred from other hospitals who travel significant distances.
“Our study is looking at patients’ postal codes, their distance to JHCC, and any impact on outcomes. We don’t know, at this time, if there is any impact but we do know, for patients needing CAR T-cell therapy, it’s vital to move quickly.”
The CAR T-cell registry,created and maintained by Dr. Balitsky, is a crucial resource for supporting cutting-edge research. As an example, a completed study led by Dr. Balitsky, currently under review for publication, utilized the registry to gain insights into the rate of secondary cancers following CAR T-cell therapy.
“We’re learning from today’s patients, to hopefully help them have the best outcomes as well as building an improved quality of life for tomorrow’s patients,” Balitsky says.
CAR T-Cell Therapy: Understanding this Innovative Lymphoma Treatment
CAR T-cell therapy is a revolutionary form of immunotherapy offering new hope for lymphoma patients. This Q&A article explores the intricacies of this treatment, its benefits, potential side effects, and ongoing research aimed at improving long-term outcomes.
Q: what is CAR T-cell therapy?
A: CAR T-cell therapy is a type of immunotherapy that uses a patient’s own T-cells to fight cancer. During this process, T-cells are extracted from the patient’s blood and genetically modified in a laboratory to express a chimeric antigen receptor (CAR) on their surface. This CAR enables the T-cells to recognize and bind to a specific protein (antigen) found on cancer cells. the modified T-cells, now CAR T-cells, are then infused back into the patient, where they can target and destroy cancer cells. This targeted approach aims to eliminate cancer cells while minimizing damage to healthy tissues.
Q: How does CAR T-cell therapy work in treating lymphoma?
A: In lymphoma treatment,CAR T-cells are engineered to recognize specific antigens found on lymphoma cells,such as CD19 or CD30. Once infused into the patient, the CAR T-cells circulate in the bloodstream, seeking out lymphoma cells expressing the target antigen. When a CAR T-cell encounters a lymphoma cell, it binds to it, triggering an immune response that leads to the destruction of the cancer cell.This process can induce remission, even in cases where other treatments have failed [Source: Article].
Q: What types of lymphoma can be treated with CAR T-cell therapy?
A: CAR T-cell therapy is approved for certain types of lymphoma, typically those that have relapsed or are refractory (have not responded) to other treatments, such as chemotherapy.These lymphoma types include:
Diffuse large B-cell lymphoma (DLBCL): The most common type of non-Hodgkin lymphoma.
Primary mediastinal large B-cell lymphoma (PMBCL)
Transformed follicular lymphoma: Follicular lymphoma that has changed into a more aggressive type of lymphoma
Mantle cell lymphoma (MCL): Another type of non-Hodgkin lymphoma.
Q: Where in Canada is CAR T-cell therapy available for lymphoma patients?
A: As of 2020, the Juravinski Hospital and Cancer Center (JHCC) at Hamilton Health Sciences (HHS) was the first hospital in Ontario to offer CAR T-cell therapy to lymphoma patients and the first in Canada to provide it on an outpatient basis [Source: Article]. It serves patients in south-central Ontario, including those referred from other hospitals. The article implies that Dr. Balitsky’s CAR T-cell registry coudl identify a thorough list of other CAR T-cell centers.
Q: What are the potential side effects of CAR T-cell therapy?
A: CAR T-cell therapy can cause significant side effects, including:
Cytokine release syndrome (CRS): This occurs when the activated CAR T-cells release large amounts of cytokines, leading to systemic inflammation. Symptoms can range from fever, chills, and fatigue to more severe complications like low blood pressure, difficulty breathing, and organ dysfunction [Source: Article].
Neurotoxicity: CAR T-cell therapy can affect the nervous system, leading to neurological problems such as confusion, seizures, speech difficulties, and even brain swelling (encephalopathy) [Source: Article].
Low blood cell counts (cytopenias): CAR T-cell therapy can suppress the bone marrow, leading to a decrease in white blood cells (neutropenia), red blood cells (anemia), and platelets (thrombocytopenia), increasing the risk of infection and bleeding.
Secondary cancers: Initial insight gained into secondary cancers following CAR T-cell therapy was gained from the CAR T-cell registry [Source: Article].
Q: How is cytokine release syndrome (CRS) managed?
A: CRS is managed with medications that block the effects of cytokines, such as tocilizumab (an interleukin-6 receptor antagonist) and corticosteroids. Supportive care, including intravenous fluids, oxygen, and blood pressure support, may also be necessary.
Q: What is the risk of long-term cognitive issues after CAR T-cell therapy and what is being done about it?
A: The long-term effects of CAR T-cell therapy on cognitive function are still being investigated. There is concern that the inflammation associated with CAR T-cell therapy, notably brain inflammation, may lead to subtle, long-term cognitive problems. Dr. Amaris Balitsky is currently conducting a study to examine long-term cognition in lymphoma patients undergoing CAR T-cell therapy, with initial data expected in January 2026 [source: Article]. This study includes cognitive tests before treatment and one year after, as well as patient-reported assessments of fatigue, depression, anxiety, and overall quality of life.
Q: Is there any impact on outcomes for patients who live further away from CAR T-cell therapy centers?
A: Dr. Balitsky’s research is investigating whether the distance patients travel to receive CAR T-cell therapy at JHCC impacts their outcomes.Data on patients’ postal codes, distance to JHCC, and treatment outcomes are being analyzed to determine if there is any correlation [Source: Article]. The findings will help inform strategies to ensure equitable access to this treatment for all patients, nonetheless of their geographic location, particularly given the importance of moving quickly once CAR T-cell therapy is deemed necessary.
Q: What is a CAR T-cell registry and why is it important?
A: A CAR T-cell registry is a database that collects comprehensive data on patients who have received CAR T-cell therapy. Dr.Balitsky created and maintains a CAR T-cell registry,which is a crucial resource for supporting cutting-edge research [Source: Article]. The registry allows researchers to track long-term outcomes, identify potential complications, and evaluate the effectiveness of CAR T-cell therapy in different patient populations. The mentioned study on secondary cancers after CAR T-cell therapy used this registry [Source: Article].